

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Maria G. Button,**

*Director, Division of the Executive Secretariat.*

[FR Doc. 2019-18646 Filed 8-28-19; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the President's Council on Sports, Fitness, and Nutrition

**AGENCY:** Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services (HHS) is hereby giving notice that the President's Council on Sports, Fitness, and Nutrition (PCSFN) will hold its annual meeting. The meeting will be open to the public.

**DATES:** The meeting will be held on September 19, 2019, from 1:00 p.m. to 4:30 p.m.

**ADDRESSES:** The Hubert H. Humphrey Building, the Great Hall, 200 Independence Ave. SW, Washington, DC 20201.

**FOR FURTHER INFORMATION CONTACT:** Jennifer Anne Bishop, Designated Federal Officer for the PCSFN, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852, (240) 453-8826. Information about PCSFN, including details about the upcoming meeting, can be obtained at [www.fitness.gov](http://www.fitness.gov).

**SUPPLEMENTARY INFORMATION:** The primary functions of the PCSFN include: (1) Advising the President, through the Secretary, concerning progress made in carrying out the provisions of Executive Order 13265, as amended by Executive Order 13824, and recommending to the President, through the Secretary, actions to accelerate such progress; and (2) recommending to the Secretary actions to expand opportunities at the national, state, and local levels for participation in sports and engagement in physical fitness and

activity, taking into account the Department of Health and Human Services' Physical Activity Guidelines for Americans, including consideration for youth with disabilities. Recommendations may address, but are not necessarily limited to: Increasing awareness of the benefits of participation in sports and regular physical activity and good nutrition; promoting private and public sector strategies to increase participation in sports; identifying metrics to gauge youth sports participation and physical activity; and discussing a national and local strategy to recruit volunteers who will support youth participation in sports and regular physical activity.

The Council shall meet, at a minimum, once per fiscal year. At the September 2019 meeting, the Council will (1) discuss activities related to a HHS National Youth Sports Strategy; and (2) discuss actions to expand opportunities at the national, state, and local levels for participation in sports and engagement in physical fitness. The meeting agenda is in development and will be posted at [www.fitness.gov](http://www.fitness.gov) when it is finalized. The meeting on September 19, 2019, is open to the public and the media. HHS will also stream the meeting online via [HHS.gov/live](http://HHS.gov/live). Every effort will be made to provide reasonable accommodations for individuals with disabilities and/or special needs who wish to attend the meeting. Individuals who require accommodations should call (240) 276-9567 to submit a request, no later than 5:00 p.m. (Eastern Time) on Monday, September 9, 2019. Members of the public who wish to attend the meeting in-person must pre-register by emailing [rsvp.fitness@hhs.gov](mailto:rsvp.fitness@hhs.gov) or by calling (240) 276-9567. Registration for in-person public attendance must be completed before 5:00 p.m. (Eastern Time) on Wednesday, September 11, 2019. Foreign nationals who wish to attend in-person should register no later than Tuesday, September 3, 2019 to ensure sufficient time for federal building security approval.

Dated: August 16, 2019.

**Don Wright,**

*Deputy Assistant Secretary for Health, Office of Disease Prevention and Health Promotion.*

[FR Doc. 2019-18726 Filed 8-28-19; 8:45 am]

**BILLING CODE 4150-32-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Dental & Craniofacial Research; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the NIDCR Special Grants Review Committee, which was published in the **Federal Register** on February 15, 2019, 84 FR 4495, page 02428.

The meeting is being amended to change location from Westgate Hotel to Embassy Suites DC Convention Center. The meeting is closed to the public.

Dated: August 23, 2019.

**Sylvia L. Neal,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-18644 Filed 8-28-19; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Genetically-Modified Lymphocytes for Cancer Therapy

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Intima Bioscience, Inc. ("Intima"), headquartered in New York, NY.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before September 13, 2019 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702; Telephone: (240) 276-5484; Facsimile: (240) 276-5504; Email: [andy.burke@nih.gov](mailto:andy.burke@nih.gov).

**SUPPLEMENTARY INFORMATION:****Intellectual Property****Group A***Intracellular Genomic Transplant and Methods of Therapy*

1. International Patent Application PCT/US2016/044856, filed July 29, 2016 (E-171-2018-6-PCT-01).

**Group B***Modified Cells and Methods of Therapy*

1. International Patent Application PCT/US2016/044858, filed July 29, 2016 (E-171-2018-7-PCT-01);

2. Canadian Patent Application 2993431, priority to July 31, 2015 (E-171-2018-7-CA-02);

3. European Patent Application 16833645.1, priority to July 31, 2015 (E-171-2018-7-EP-03);

4. Israeli Patent Application 257105, priority to July 31, 2015 (E-171-2018-7-IL-04);

5. Chinese Patent Application 201680059180.8, priority to July 31, 2015 (E-171-2018-7-CN-05);

6. United Kingdom Patent Application 1803280.5, priority to July 31, 2015 (E-171-2018-7-GB-06);

7. Japanese Patent Application 2018-525531, priority to July 31, 2015 (E-171-2018-7-JP-07);

8. Hong Kong Patent Application 18115478.9, priority to July 31, 2015 (E-171-2018-7-HK-08);

9. United States Patent 10,166,255, issued January 1, 2019 (E-171-2018-8-US-01);

10. United States Patent Application 16/180,867, filed July 29, 2016 (E-171-2018-8-US-02);

11. United States Patent Application 16/182,146, filed November 3, 2018 (E-171-2018-8-US-03);

12. United States Patent Application 16/182,189, filed November 6, 2018 (E-171-2018-8-US-04);

13. United States Patent Application 15/224,159, filed July 29, 2016 (E-171-2018-9-US-01);

14. United States Patent Application 15/250,514, filed August 29, 2016 (E-171-2018-9-US-02);

15. United States Patent Application 15/256,086, filed September 2, 2016 (E-171-2018-9-US-03); and

16. United States Patent Application 16/513,933, filed July 17, 2019 (E-171-2018-9-US-04).

**Group C***Viral Methods of T Cell Therapy*

1. International Patent Application PCT/US2017/058615, filed October 26, 2017 (E-173-2018-2-PCT-01);

2. United States Patent Application 16/389,586, filed April 19, 2019 (E-173-2018-2-US-02);

3. Australian Patent Application 2017347854, priority to October 26, 2016 (E-173-2018-2-AU-03);

4. Canadian Patent Application 3,041,835, priority to October 26, 2016 (E-173-2018-2-CA-04);

5. European Patent Application 17865054.5, priority to October 26, 2016 (E-173-2018-2-EP-05);

6. Japanese Patent Application 2019-522944, priority to October 26, 2016 (E-173-2018-2-JP-06);

7. Chinese Patent Application [awaiting application number], priority to October 26, 2016 (E-173-2018-2-CN-07); and

8. United Kingdom Patent Application 1906850.1, priority to October 26, 2016 (E-173-2018-2-GB-08).

**Group D***CAS9 Modified TIL for Treatment of Gastrointestinal Cancer*

1. International Patent Application PCT/US2017/057228, filed October 18, 2017 (E-174-2018-2-PCT-01);

2. United States Patent Application 15/947,688, filed April 6, 2018 (E-174-2018-2-US-02);

3. United Kingdom Patent Application 1906855.0, priority to October 18, 2016 (E-174-2018-2-GB-03).

4. Australian Patent Application 2017346885, priority to October 18, 2016 (E-174-2018-2-AU-04);

5. Canadian Patent Application 3,041,068, priority to October 18, 2016 (E-174-2018-2-CA-05);

6. Chinese Patent Application, 2017800784716, priority to October 18, 2016 (E-174-2018-2-CN-06);

7. Japanese Patent Application, 2019-520738, priority to October 18, 2016 (E-174-2018-2-JP-08); and

8. European Patent Application, 17861792.4, priority to October 18, 2016 (E-174-2018-2-EP-09).

The patent rights in these inventions are co-owned by (a) the United States of America, as represented by the Secretary, Department of Health and Human Services, (b) Regents of the University of Minnesota, and (c) Intima Bioscience, Inc.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

“Autologous T cell therapy products genetically engineered by CRISPR to specifically reduce expression or activity of a checkpoint gene (e.g. CISH, PD-1 or CTLA-4) for the treatment of

gastrointestinal (GI) epithelial cancer, lung cancer, breast cancer and/or B cell lymphoma (BCL) in humans.

Autologous T cell therapy products (excluding tumor infiltrating lymphocytes) genetically engineered by CRISPR or adeno-associated viral vectors to express exogenous, tumor-reactive T cell receptors for the treatment of gastrointestinal (GI) epithelial cancer, lung cancer, breast cancer and/or B cell lymphoma (BCL) in humans.

Allogeneic T cell therapy products genetically engineered by CRISPR/CAS9 to specifically reduce expression or activity of a checkpoint gene for the treatment of gastrointestinal (GI) epithelial cancer, lung cancer, breast cancer and/or B cell lymphoma (BCL) in humans.

Allogeneic T cell therapy products genetically engineered by CRISPR/CAS9 or adeno-associated viral vectors to express exogenous, tumor-reactive T cell receptors for the treatment of gastrointestinal (GI) epithelial cancer, lung cancer, breast cancer and/or B cell lymphoma (BCL) in humans.”

Intellectual Property Group A is primarily directed to methods and compositions relating to the generation of T cells engineered to contain multiple genomic disruptions and methods of treating cancer using the same.

Intellectual Property Group B is primarily directed to methods and compositions relating to the generation of T cells genetically engineered to express an exogenous T cell receptor and a genomic disruption in a checkpoint gene and methods of treating cancer using the same.

Intellectual Property Group C is primarily directed to methods and compositions relating to the generation of T cells genetically engineered by CRISPR and adeno-associated viral vectors to coordinately introduce a genomic disruption in a checkpoint gene and an exogenous T cell receptor, and methods of treating cancer using the same.

Intellectual Property Group D is primarily directed to methods and compositions relating to the generation of tumor infiltrating lymphocytes comprising a genomic disruption in the checkpoint gene *CISH* and methods of treating cancer using the same.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument which

establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2019.

**Richard U. Rodriguez,**  
*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2019-18648 Filed 8-28-19; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Member Conflict: Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Review Committee.

*Date:* October 29, 2019.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Arthritis and Musculoskeletal and Skin Diseases, Democracy One, 6701 Democracy Blvd., Suite 800, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Kathy Salaita, SCD, Chief, Scientific Review Branch, DHHS/NIH/

NIAMS, One Democracy Plaza, Suite 800, 6701 Democracy Blvd., MSC 4872, Bethesda, MD 20892, 301-594-5033, *Kathy.Salaita@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: August 23, 2019.

**Sylvia L. Neal,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-18642 Filed 8-28-19; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Research to Improve Native American Health.

*Date:* September 25, 2019.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

*Contact Person:* Lauren Fordyce, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3214, Bethesda, MD 20892, 301-827-8269, *fordycelem@mail.nih.gov*.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Improving Animal Models of Influenza Infection that are Predictive of Human Immunity and Vaccination.

*Date:* September 25, 2019.

*Time:* 11:00 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Kenneth M Izumi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3204, MSC 7808, Bethesda, MD 20892, 301-496-6980, *izumikm@csr.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: August 23, 2019.

**Sylvia L. Neal,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2019-18643 Filed 8-28-19; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG-2019-0704]

#### Cooperative Research and Development Agreement: Cell Phone Geolocation for USCG Search and Rescue

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice of intent; request for public comments.

**SUMMARY:** The Coast Guard announces its Cooperative Research and Development Agreement (CRADA) with Callyo 2009 Corporation, to investigate the potential operational use of leveraging smart phone technology, specifically the phone's location services, to help locate mariners in distress more efficiently. The CRADA with Callyo 2009 Corporation is based on market research and visits to vendors with advertised expertise in this unique application of technology in the maritime environment for Search and Rescue. While the Coast Guard is currently partnering with Callyo 2009 Corporation, the agency is soliciting public comment on the possible nature of and participation of other parties in the proposed CRADA. In addition, the Coast Guard also invites other potential non-Federal participants, who have the interest and capability to bring similar contributions to this type of research, to consider submitting proposals for consideration in similar CRADAs.

**DATES:** Comments must be submitted to the online docket via <http://www.regulations.gov> on or before September 9, 2019.

Synopses of proposals regarding future CRADAs must reach the Coast Guard (see **FOR FURTHER INFORMATION**